Haematologica (Dec 2017)
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
- Ibrahim Aldoss,
- Anh Pham,
- Sierra Min Li,
- Ketevan Gendzekhadze,
- Michelle Afkhami,
- Milhan Telatar,
- Hao Hong,
- Abbas Padeganeh,
- Victoria Bedell,
- Thai Cao,
- Samer K Khaled,
- Monzr M Al Malki,
- Amandeep Salhotra,
- Haris Ali,
- Ahmed Aribi,
- Joycelynne Palmer,
- Patricia Aoun,
- Ricardo Spielberger,
- Anthony S Stein,
- David Snyder,
- Margaret R O’Donnell,
- Joyce Murata-Collins,
- David Senitzer,
- Dennis Weisenburger,
- Stephen J Forman,
- Vinod Pullarkat,
- Guido Marcucci,
- Raju Pillai,
- Ryotaro Nakamura
Affiliations
- Ibrahim Aldoss
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Anh Pham
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Sierra Min Li
- Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA
- Ketevan Gendzekhadze
- HLA Laboratory, City of Hope, Duarte, CA, USA
- Michelle Afkhami
- Department of Pathology, City of Hope, Duarte, CA, USA
- Milhan Telatar
- Department of Pathology, City of Hope, Duarte, CA, USA
- Hao Hong
- Department of Pathology, City of Hope, Duarte, CA, USA
- Abbas Padeganeh
- Department of Cytogenetics, City of Hope, Duarte, CA, USA
- Victoria Bedell
- Department of Cytogenetics, City of Hope, Duarte, CA, USA
- Thai Cao
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Samer K Khaled
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Monzr M Al Malki
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Amandeep Salhotra
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Haris Ali
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Ahmed Aribi
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Joycelynne Palmer
- Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA
- Patricia Aoun
- Department of Pathology, City of Hope, Duarte, CA, USA
- Ricardo Spielberger
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Anthony S Stein
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- David Snyder
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Margaret R O’Donnell
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Joyce Murata-Collins
- Department of Cytogenetics, City of Hope, Duarte, CA, USA
- David Senitzer
- HLA Laboratory, City of Hope, Duarte, CA, USA
- Dennis Weisenburger
- Department of Pathology, City of Hope, Duarte, CA, USA
- Stephen J Forman
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Vinod Pullarkat
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Guido Marcucci
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- Raju Pillai
- Department of Pathology, City of Hope, Duarte, CA, USA
- Ryotaro Nakamura
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA
- DOI
- https://doi.org/10.3324/haematol.2017.172544
- Journal volume & issue
-
Vol. 102,
no. 12
Abstract
Therapy-related myelodysplastic syndrome is a long-term complication of cancer treatment in patients receiving cytotoxic therapy, characterized by high-risk genetics and poor outcomes. Allogeneic hematopoietic cell transplantation is the only potential cure for this disease, but the prognostic impact of pre-transplant genetics and clinical features has not yet been fully characterized. We report here the genetic and clinical characteristics and outcomes of a relatively large cohort of patients with therapy-related myelodysplastic syndrome (n=67) who underwent allogeneic transplantation, comparing these patients to similarly treated patients with de novo disease (n=199). The 5-year overall survival was not different between patients with therapy-related and de novo disease (49.9% versus 53.9%; P=0.61) despite a higher proportion of individuals with an Intermediate-2/High International Prognostic Scoring System classification (59.7% versus 43.7%; P=0.003) and high-risk karyotypes (61.2% versus 30.7%; P
